scholarly journals Effect of Treatment Expectation on Placebo Response and Analgesic Efficacy

2020 ◽  
Vol 3 (4) ◽  
pp. e202907
Author(s):  
Anne E. Sanders ◽  
Gary D. Slade ◽  
Roger B. Fillingim ◽  
Richard Ohrbach ◽  
Samuel J. Arbes ◽  
...  
2016 ◽  
Vol 18 (11) ◽  
pp. 906-912 ◽  
Author(s):  
Javier Benito ◽  
Beatriz Monteiro ◽  
Anne-Marie Lavoie ◽  
Guy Beauchamp ◽  
B Duncan X Lascelles ◽  
...  

Objectives The aim of this study was to evaluate the analgesic efficacy of intraperitoneal (IP) bupivacaine in cats undergoing ovariohysterectomy (OVH). Methods Forty-five cats were included in a randomized, prospective, blinded study after owners’ written consent was obtained. The anesthetic protocol included acepromazine–buprenorphine–propofol–isoflurane. A ventral midline incision was made and cats (n = 15/group) were administered either IP saline 0.9% (negative and positive control groups; NG and PG, respectively) or IP bupivacaine (2 mg/kg; bupivacaine group; BG). Cats in the PG received meloxicam (0.2 mg/kg SC). An OVH was performed and postoperative pain was evaluated using a dynamic interactive visual analog scale (DIVAS), the UNESP-Botucatu multidimensional composite pain scale (MCPS) and mechanical nociceptive thresholds (MNT) for up to 8 h after the end of surgery. Postoperative sedation was evaluated using DIVAS. Rescue analgesia was provided with buprenorphine and/or meloxicam. Repeated measures linear models and a Cochran–Mantel–Haenszel test were used for statistical analysis ( P <0.05). Results There was a significant effect of treatment on the number of times rescue analgesia was administered ( P = 0.002) (PG, n = 2, 13%; NG, n = 12, 80%; BG, n = 4, 27%) with the number of rescues being higher in the NG group than in the PG ( P = 0.0004) and BG ( P = 0.02) groups. The DIVAS, MCPS and MNT were significantly different when compared with baseline values at different time points; however, data were not significantly different among groups. Conclusions and relevance Treatments PG and BG produced similar analgesia in terms of pain scores, number of times rescue analgesia was administered and MNT. Based on rescue analgesia, IP administration of bupivacaine provides analgesia in cats after OVH.


2011 ◽  
Vol 3 (70) ◽  
pp. 70ra14-70ra14 ◽  
Author(s):  
U. Bingel ◽  
V. Wanigasekera ◽  
K. Wiech ◽  
R. Ni Mhuircheartaigh ◽  
M. C. Lee ◽  
...  

Spine ◽  
2008 ◽  
Vol &NA; ◽  
pp. 131
Author(s):  
Lurie Jon ◽  
Berven Sigurd ◽  
Blood Emily ◽  
Tosteson Anna ◽  
Spratt Kevin ◽  
...  

2001 ◽  
Vol 120 (5) ◽  
pp. A640-A640 ◽  
Author(s):  
A NORTHCUTT ◽  
A MANGEL ◽  
L HAMM ◽  
J HARDING ◽  
N LOTAY ◽  
...  

2004 ◽  
Vol 171 (4S) ◽  
pp. 294-294
Author(s):  
Yufeng Zhou ◽  
Charles G. Marguet ◽  
Michaella E. Maloney ◽  
Franklin H. Cocks ◽  
Glenn M. Preminger ◽  
...  

2014 ◽  
Vol 222 (3) ◽  
pp. 148-153 ◽  
Author(s):  
Sabine Vits ◽  
Manfred Schedlowski

Associative learning processes are one of the major neuropsychological mechanisms steering the placebo response in different physiological systems and end organ functions. Learned placebo effects on immune functions are based on the bidirectional communication between the central nervous system (CNS) and the peripheral immune system. Based on this “hardware,” experimental evidence in animals and humans showed that humoral and cellular immune functions can be affected by behavioral conditioning processes. We will first highlight and summarize data documenting the variety of experimental approaches conditioning protocols employed, affecting different immunological functions by associative learning. Taking a well-established paradigm employing a conditioned taste aversion model in rats with the immunosuppressive drug cyclosporine A (CsA) as an unconditioned stimulus (US) as an example, we will then summarize the efferent and afferent communication pathways as well as central processes activated during a learned immunosuppression. In addition, the potential clinical relevance of learned placebo effects on the outcome of immune-related diseases has been demonstrated in a number of different clinical conditions in rodents. More importantly, the learned immunosuppression is not restricted to experimental animals but can be also induced in humans. These data so far show that (i) behavioral conditioned immunosuppression is not limited to a single event but can be reproduced over time, (ii) immunosuppression cannot be induced by mere expectation, (iii) psychological and biological variables can be identified as predictors for this learned immunosuppression. Together with experimental approaches employing a placebo-controlled dose reduction these data provide a basis for new therapeutic approaches to the treatment of diseases where a suppression of immune functions is required via modulation of nervous system-immune system communication by learned placebo effects.


Sign in / Sign up

Export Citation Format

Share Document